Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

• Sponsor: Astex Pharmaceuticals, Inc. (Industry)
• Overall Status: Withdrawn
• CT.gov ID: NCT01239108
• Collaborator: (none)
• Enrollment: 0
• Location: 1
• Duration (Months): 18
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.

Condition or Disease	Intervention/Treatment	Phase
Relapsed/Refractory Leukemias	Drug: SGI-1776	Phase 1

Detailed Description

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects with Relapsed/Refractory Leukemias

Study Design

• Study Type: Interventional
• Actual Enrollment: 0 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
• Study Start Date: Oct 1, 2010
• Anticipated Primary Completion Date: Apr 1, 2012
• Anticipated Study Completion Date: Apr 1, 2012

Outcome Measures

Primary Outcome Measures

1. The MTD as determined by the incidence of DLTs in the first 4 weeks of each dosing cohort [July 2011]

Secondary Outcome Measures

1. • Frequency, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs) • [1 year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Men and women with a confirmed diagnosis of leukemia unresponsive to curative therapy

2. Eastern Cooperative Oncology Group performance status of 0 to 2

3. Total bilirubin ≤ 1.5 X upper limit of normal (ULN); aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤ 3 X ULN; serum creatinine ≤ 2 X ULN

4. Normal cardiac function with left ventricular ejection fraction ≥ 50% at screening

5. No clinically significant abnormalities on screening electrocardiogram (ie, QTc interval must be < 470 msec for women and < 450 msec for men and no history of torsades de pointes)

6. No reproductive potential or willing to use 2 methods of contraception during the study and for 30 days after the last dose

7. Able to understand the purpose and risks of the study and provide informed consent and authorization to use protected health information

Exclusion Criteria:

1. A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral SGI-1776, or put the study outcomes at undue risk

2. Significant cardiovascular disease

3. Malabsorption syndrome

4. Symptomatic central nervous system metastases or lesions for which treatment is required

5. Received prior radiation therapy within 4 weeks of first dose

6. Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation

7. Treatment with any investigational drug within 3 weeks of the first dose

8. Use of systemic corticosteroids (other than for premedications or intermittent doses such as those used for allergic reactions and control of asthma) or myelosuppressive chemotherapy within 2 weeks of the first dose treatment with nitrosoureas or mitomycin C within 3 weeks of the first dose of SGI 1776

9. Uncontrolled active systemic infections

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	MD Anderson Cancer Center	Houston	Texas	United States

Sponsors and Collaborators

• Astex Pharmaceuticals, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Astex Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT01239108
• Other Study ID Numbers: SGI-1776-02
• First Posted: Nov 11, 2010
• Last Update Posted: Jan 18, 2020
• Last Verified: Jan 1, 2020

• Additional relevant MeSH terms: Leukemia

Study Results

No Results Posted as of Jan 18, 2020